Phenotype description and response to thrombopoietin receptor agonist in DIAPH1-related disorder

NIHR BioResource–Rare Diseases

Research output: Contribution to journalArticle (Academic Journal)peer-review

10 Citations (Scopus)
201 Downloads (Pure)

Abstract

The heritable thrombocytopenias (HTs) are genetically heterogeneous rare disorders in which
reduced circulating platelet levels may be associated with nonhematological features. Among
recently discovered HTs, DIAPH1-related disorder (D-RD; OMIM #124900) was initially reported in
pedigrees with macrothrombocytopenia and hearing loss. This phenotype segregated with a
heterozygous p.R1213* variant in DIAPH1, which encodes the cytoskeletal regulator diaphanous
homolog 1 (DIAPH1). This predicted truncation of the DIAPH1 C terminus diaphanous autoregulatory domain (DAD) and was proposed to confer gain-of-function, resulting in megakaryocyte (MK) cytoskeletal dysregulation and impaired proplatelet formation. Macrothrombocytopenia and hearing loss have subsequently been reported in further isolated pedigrees with DAD DIAPH1 variants,4-6 suggesting that D-RD is a distinct syndromic HT. However, other descriptions of similar DIAPH1 variants include hearing loss but not hematological findings. To provide a full phenotypic description of D-RD and the relationship with different DIAPH1 variants, we report detailed hematological findings from 5 D-RD pedigrees, including the in vitro response and clinical outcome of treatment with the thrombopoietin (TPO) receptor agonist
eltrombopag.
Original languageEnglish
Pages (from-to)2341-2346
Number of pages6
JournalBlood Advances
Volume2
Issue number18
Early online date19 Sep 2018
DOIs
Publication statusPublished - 25 Sep 2018

Fingerprint Dive into the research topics of 'Phenotype description and response to thrombopoietin receptor agonist in DIAPH1-related disorder'. Together they form a unique fingerprint.

Cite this